Clarivate Analytics, a global insights and analytics company, announced the launch of its annual “Cortellis Drugs to Watch” report using data and analytics from Cortellis, the company’s suite of life science intelligence solutions. The report highlights seven new drugs forecasted to sell at blockbuster status ($1billion or higher) by 2023.
The drugs include Upadacitinib (AbbVie – US), which treats rheumatoid arthritis; Zolgensma (AveXis – US), which treats spinal muscular atrophy; Roxadustat (AstraZeneca – UK, FibroGen – US, Astellas – Japan), which treats anemia in chronic kidney disease patients on dialysis; Ultomiris (Alexion – US), which treats paroxysmal nocturnal hemoglobinuria; Skyrizi (Boehringer Ingelheim – DE, AbbVie – US), which treats psoriasis; AR-101 (Aimmune Therapeutics – US), which treats peanut allergies; and LentiGlobin (bluebird bio – US), which treats beta-thalassemia in transfusion-dependent patients.
For more information about each drug, how much is forecasted in sales for 2023, and to download the full report, visit here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.